PTO/SB/30 (08-03) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are require

Request For Continued Examination (RCE) **Transmittal**

Address to: Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

ed to respond to a collection of informa	tion unless it contains a valid OMB control number.
Application Number	09/815,362
Filing Date	March 21, 2001
First Named Inventor	Chow et al_
Art Unit	1626
Examiner Name	Rebecca L. Anderson
Attorney Docket Number	17243CIP3(AP)

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1. Submission required under 37 CFR 1.114 Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).	
a. Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.	
i. Consider the arguments in the Appeal Brief or Rely Brief previously filed on	
li. Uther Other	
b. X Enclosed	
I. X Amendment/Reply iii. Information Disclosure Statement (IDS)	
ii. Affidavit(s)/ Declaration(s) iv. Other	
2. Miscellaneous	
Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a	
a period of months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required) b Other	
The BOE fee under 27 CEB 4 47(s) is required by 27 CEB 4 444 when the BOE is filed	
3. Fees The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed. The Director is hereby authorized to charge the following fees, or credit any overpayments, to	
The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 01-0885	
i. X RCE fee required under 37 CFR 1.17(e)	
ii. X Extension of time fee (37 CFR 1.136 and 1.17)	
iii. Other	
b. Check in the amount of \$enclosed	
c. Payment by credit card (Form PTO-2038 enclosed)	
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.	
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED	
Name (Print/Type) Carlos A. Fisher Registration No., (Attomey/Agent) 36.510 Signature Date Color Carlos A. Fisher Date Carlos A. Fisher Carlos A. Fisher Carlos A. Fisher Date Carlos A. Fisher Ca	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.	
Name (Print/Type) BOUDLE FERGUSON	
Signature Date Q/10/2004 S This collection of information is required by 37 CFR 1 114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO S	

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



DOCKET NO. 17243CIP3(AP) **PATENT**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of Chow et al

Serial No: 09/815,362; Conf. No. 4078

Filed: March 21, 2001

COMPOUNDS AND METHODS OF TREATMENT HAVING AGONIST-LIKE ACTIVITY SELECTIVE AT ALPHA 2B OR 2B/2C ADRENERGIC RECEPTORS

Group Art Unit: 1626

Examiner: Anderson, Rebecca L.

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on:

AMENDMENT

Commissioner for Patents Alexandria, VA 22313-1450

Dear Sir:

Applicant hereby files a response to the outstanding Office Action. This communication is being filed with a Request for Continued Prosecution.